Mei Hou

6.6k total citations · 1 hit paper
38 papers, 2.5k citations indexed

About

Mei Hou is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Mei Hou has authored 38 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Mei Hou's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (14 papers) and Colorectal Cancer Treatments and Studies (7 papers). Mei Hou is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (14 papers) and Colorectal Cancer Treatments and Studies (7 papers). Mei Hou collaborates with scholars based in China, United Kingdom and Thailand. Mei Hou's co-authors include Chengping Hu, Shun Lü, Yi‐Long Wu, Jifeng Feng, Jian Hua Shi, Yunchao Huang, Dan Massey, Kye Young Lee, Sarayut Lucien Geater and Wěi Li and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Mei Hou

38 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

2014 1.6k citations Yi‐Long Wu, Caicun Zhou et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Mei Hou

Since Specialization

Citations

This map shows the geographic impact of Mei Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei Hou more than expected).

Fields of papers citing papers by Mei Hou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mei Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei Hou. The network helps show where Mei Hou may publish in the future.

Co-authorship network of co-authors of Mei Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Mei Hou. A scholar is included among the top collaborators of Mei Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mei Hou. Mei Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CD8+ T and NK cells characterized by upregulation of NPEPPS and ABHD17A are associated with the co-occurrence of type 2 diabetes and coronary artery disease 2024 ·Frontiers in Immunology ·(unknown), (unknown), (unknown), Ziyi Li, (unknown), Yingying Wang, Mei Hou, Simin Cheng, Wentao Qi, Longyi Zheng, (unknown)	5
2	ZmSPL13andZmSPL29act together to promote vegetative and reproductive transition in maize 2023 ·New Phytologist ·Juan Yang, Hongbin Wei, Mei Hou, Lihong Chen, (unknown), (unknown), Yifeng Jing, (unknown), Yongping Zhao, (unknown), Yueqin Heng, Hong Wu, Baobao Wang, Dexin Kong, Haiyang Wang	18
3	A deep learning method for optimizing semantic segmentation accuracy of remote sensing images based on improved UNet 2023 ·Scientific Reports ·Xiaolei Wang, (unknown), (unknown), Mei Hou, Lei Xu, (unknown)	48
4	Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring <em>EGFR </em>mutations: subgroup analysis of the LUX-Lung 6 trial 2018 ·OncoTargets and Therapy ·Yi‐Long Wu, Chong‐Rui Xu, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wu Li, Mei Hou, Jian Hua Shi, Angela Märten, Jean Fan, Barbara Peil, Caicun Zhou	21
5	Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study 2016 ·Lung Cancer ·Lin Zhou, (unknown), (unknown), Yongmei Liu, (unknown), Yu Qin, Maozhi Liang, Xiaojuan Zhou, Zhenyu Ding, Meijuan Huang, Li Ren, Jiang Zhu, Lu Li, Mei Hou, Lieming Ding, Fenlai Tan, You Lü	26
6	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 2016 ·British Journal of Cancer ·Yi‐Long Wu, Lecia V. Sequist, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wei Li, Mei Hou, Martin Schüler, Tony Mok, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Neil Gibson, Dan Massey, Miyoung Kim, James Chih‐Hsin Yang	70
7	Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer 2016 ·BMC Cancer ·Yan Sun, Ying Cheng, Xuezhi Hao, Jie Wang, Chengping Hu, Baohui Han, Xiaoqing Liu, Li Zhang, (unknown), Zhongjun Xia, Yunpeng Liu, (unknown), Mei Hou, Helong Zhang, Qingyu Xiu, Yunzhong Zhu, Jifeng Feng, Shukui Qin, Xiaoyan Luo	35
8	Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer 2015 ·Journal of Thoracic Oncology ·Sarayut Lucien Geater, Chong‐Rui Xu, Caicun Zhou, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wěi Li, Mei Hou, Jian Hua Shi, Kye Young Lee, Michael Palmer, Yang Shi, Juliane Lungershausen, Yi‐Long Wu	49
9	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial breakdown → 2014 ·The Lancet Oncology ·Yi‐Long Wu, Caicun Zhou, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wěi Li, Mei Hou, Jian Hua Shi, Kye Young Lee, Chong‐Rui Xu, Dan Massey, Miyoung Kim, Yang Shi, Sarayut Lucien Geater	1574
10	Polymorphisms in DNA repair genes of XRCC1, XPA, XPC, XPD and associations with lung cancer risk in Chinese people 2013 ·Thoracic Cancer ·(unknown), Mei Hou, (unknown), Hua Feng, (unknown), Feng Xu, Yong Jiang, Lu Li, You‐Lin Qiao, Yaguang Fan, Qinghua Zhou	16
11	[Advanced research of fibroblast growth factor receptor in non-small cell lung cancer]. 2013 ·SHILAP Revista de lepidopterología ·Dan Pu, Mei Hou	2
12	[A randomized controlled study of chemotherapy: etoposide combined with oxaliplatin or cisplatin regimens in the treatment of extensive-stage small cell lung cancer in elderly patients]. 2013 ·SHILAP Revista de lepidopterología ·Dan Pu, Mei Hou, Zhixi Li, Xiaomei Zeng	2
13	Salvage treatment with erlotinib after gefitinib failure in advanced non‐small‐cell lung cancer patients with poor performance status: A matched‐pair case–control study 2011 ·Thoracic Cancer ·(unknown), Meijuan Huang, Xinxing Zhang, Min Yu, Bingwen Zou, Yanying Li, Jianlin Long, Jin Wang, Feng Peng, Yong Xu, Lu Li, Li Ren, Mei Hou, You Lü	5
14	Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications 2011 ·Journal of Experimental & Clinical Cancer Research ·Hongfeng Gou, Xinchuan Chen, Jiang Zhu, Ming Jiang, Yu Yang, Dan Cao, Mei Hou	75
15	Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC) 2010 ·Medical Oncology ·Yu Yang, Jiang Zhu, Hongfeng Gou, Dan Cao, Ming Jiang, Mei Hou	49
16	A Multicenter Retrospective Analysis of Survival Outcome Following Postoperative Chemoradiotherapy in Non–Small-Cell Lung Cancer Patients With N2 Nodal Disease 2009 ·International Journal of Radiation OncologyBiologyPhysics ·Bingwen Zou, Yong Xu, Tao Li, (unknown), (unknown), Lin Zhou, Li Lu, Yongmei Liu, Jiang Zhu, Meijuan Huang, Jin Wang, Li Ren, (unknown), Guowei Che, Lunxu Liu, Mei Hou, You Lü	48
17	Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications 2009 ·BMC Cancer ·Dan Cao, Mei Hou, Yong‐Song Guan, Ming Jiang, Yang Yu, Hongfeng Gou	178
18	Nucleophilic Attack on the Carbon–Nitrogen Double Bond Leading to Tetrahedral Intermediates with Conformationally Restricted Stereochemistry 2008 ·Australian Journal of Chemistry ·James E. Johnson, (unknown), Yi Li, Mei Hou, (unknown)	2
19	Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma 2008 ·Cancer Chemotherapy and Pharmacology ·Youling Gong, Li Ren, Lin Zhou, Jiang Zhu, Meijuan Huang, Xiaojuan Zhou, Jin Wang, You Lü, Mei Hou, Yuquan Wei	26
20	Imatinib Mesylate Treatment for Advanced Gastrointestinal Stromal Tumor: A Pilot Study Focusing on Patients Experiencing Sole Liver Metastasis after a Prior Radical Resection 2007 ·Oncology ·Jiang Zhu, Yan Wang, Mei Hou, Hui Li, Jie Zhang	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact